Antihypertensive drugs and lipids
- Michael J Bloch, MD, FACP, FASH, FSVM, FNLA
Michael J Bloch, MD, FACP, FASH, FSVM, FNLA
- Associate Professor, University of Nevada School of Medicine
- Medical Director, Vascular Care, Renown Regional Medical Center
- Jan Basile, MD
Jan Basile, MD
- Professor of Medicine
- Medical University of South Carolina
- Ralph H Johnson Veterans Affairs Medical Center
- Section Editor
- George L Bakris, MD
George L Bakris, MD
- Editor-in-Chief — Nephrology
- Section Editor — Hypertension
- Professor of Medicine
- The University of Chicago
- Deputy Editors
- Daniel J Sullivan, MD, MPH
Daniel J Sullivan, MD, MPH
- Deputy Editor — Primary Care (Adult)
- Assistant Professor of Medicine
- Harvard Medical School
- John P Forman, MD, MSc
John P Forman, MD, MSc
- Senior Deputy Editor — UpToDate
- Deputy Editor — Nephrology
- Assistant Professor of Medicine
- Harvard Medical School
Drug-induced changes in lipid levels may be particularly important in hypertensive patients since up to 45 percent of untreated patients with primary hypertension (formerly called "essential" hypertension) already have lipid abnormalities, such as a high low-density lipoprotein (LDL) cholesterol . In addition, genetic studies in humans suggest that a predisposition for the development of both hypertension and dyslipidemia may result from the inheritance of shared genetic risk factors .
Treatment of hypertension can affect lipid levels, and treatment of dyslipidemia can affect blood pressure. Some antihypertensive drugs, for example, have a neutral or beneficial effect on the lipid profile while others have an adverse effect; such adverse effects are outweighed by the beneficial effects of blood pressure lowering on cardiovascular risk. In addition, lipid-lowering therapy with statins may reduce blood pressure. In general, effects of blood pressure-lowering agents on lipid levels and effects of statins on blood pressure are modest. Blood pressure lowering and lipid lowering provide independent and, at least, additive reductions in cardiovascular risk [3,4].
EFFECTS OF DIFFERENT ANTIHYPERTENSIVE AGENTS
Antihypertensive drugs with adverse effects on plasma lipid levels — Thiazide diuretics and beta blockers may adversely affect lipid levels. However, we would not avoid using these medications (if otherwise indicated) in a patient with dyslipidemia, and, similarly, we would not discontinue these medications in a patient just to improve the lipid profile .
Thiazide diuretics — Very high doses of thiazide diuretics (50 to 100 mg of hydrochlorothiazide or chlorthalidone in one study) produce an initial 5 to 10 percent elevation in total and low-density lipoprotein (LDL) cholesterol and a lesser increase in triglycerides . The hyperlipidemic effect of thiazide diuretics is dose dependent [6,7]. Contemporary doses lead to more modest effects. As an example, there is little or no effect on lipid metabolism with a daily dose of 12.5 mg of hydrochlorothiazide or its equivalent , a dose that may have an antihypertensive effect nearly as great as higher doses (see "Use of thiazide diuretics in patients with primary (essential) hypertension"). In addition, 25 mg of chlorthalidone in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) produced a slightly higher mean total cholesterol than did lisinopril or amlodipine at four years, but the mean difference was <2.5 mg/dL .
Beta blockers — Beta blockers are a heterogeneous class of antihypertensive medications. The effect of beta blockers on serum lipids varies with their unique pharmacologic characteristics and may be more prominent among smokers [7,10]. Many older, traditional beta blockers, both cardioselective and noncardioselective (such as atenolol, metoprolol, and propranolol), lead to a fairly modest increase in triglycerides (20 to 40 percent), a decrease in high-density lipoprotein (HDL) cholesterol (approximately 10 percent), and little effect on total cholesterol or LDL cholesterol [7,11]. By contrast, lipid levels are relatively unaffected by labetalol (a combined alpha and beta blocker) and beta blockers with intrinsic sympathomimetic activity (eg, acebutolol and pindolol) .To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation 2013; 128:29.
- Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988; 259:3579.
- Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27:2982.
- Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016; 374:2032.
- Mänttäri M, Tenkanen L, Manninen V, et al. Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality. Hypertension 1995; 25:47.
- Grimm RH Jr, Leon AS, Hunninghake DB, et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 1981; 94:7.
- Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.
- Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8:461.
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.
- Vyssoulis GP, Karpanou EA, Pitsavos CE, et al. Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension. Am J Cardiol 1991; 67:987.
- Wolinsky H. The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987; 10:561.
- Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955.
- Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.
- Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8:127.
- Kannel WB, Carter BL. Initial drug therapy for hypertensive patients with hyperlipidemia. Am Heart J 1989; 118:1012.
- Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5:III132.
- Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27:457.
- Kirk JK. Angiotensin-II receptor antagonists: their place in therapy. Am Fam Physician 1999; 59:3140.
- Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131:966.
- Spósito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83:1497.
- Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30:980.
- Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168:721.
- EFFECTS OF DIFFERENT ANTIHYPERTENSIVE AGENTS
- Antihypertensive drugs with adverse effects on plasma lipid levels
- - Thiazide diuretics
- - Beta blockers
- Antihypertensive drugs with neutral or beneficial effects on plasma lipid levels
- - Angiotensin-converting enzyme inhibitors
- - Angiotensin receptor blockers
- - Calcium channel blockers
- - Alpha blockers
- - Sympathetic blockers
- Effects of combination therapy
- EFFECT OF STATINS ON BLOOD PRESSURE